MoonLake Immunotherapeutics
MLTX
MLTX
113 hedge funds and large institutions have $2.99B invested in MoonLake Immunotherapeutics in 2024 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 44 increasing their positions, 37 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
113
Holders Change
-12
Holders Change %
-9.6%
% of All Funds
1.64%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.06%
New
21
Increased
44
Reduced
37
Closed
33
Calls
$22.9M
Puts
$26.9M
Net Calls
-$4.03M
Net Calls Change
+$3.54M
Top Buyers
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$38.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$26.3M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$25.7M |
| 4 |
Holocene Advisors
New York
|
+$24.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$15.1M |
Top Sellers
| 1 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$62.8M |
| 2 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$26.8M |
| 3 |
Invesco
Atlanta,
Georgia
|
-$14.4M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
-$14M |
| 5 |
SIG
Senator Investment Group
New York
|
-$9.36M |
